Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Therapy Before Tandem Melphalan in MM
NCT02288741Phase 3Completed
- Sponsor
- Wisp
- Start
- Aug 2001
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, idarubicin, vincristine sulfate liposome injection, cyclophosphamide in multiple myeloma (MM), sponsored by Wisp. Started Aug 2001; status: completed.
02
Drugs
pegylated liposomal doxorubicinidarubicinvincristine sulfate liposome injectioncyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02288741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288741.